NCT07640516 The Analgesic Efficacy of Dexmedetomidine Versus Fentanyl as an Adjuvant to Bupivacaine in Ultrasound Guided Peripheral Nerve Blocks as a Solo Anesthetic Technique in High Risk Patients Undergoing Unilateral Above Knee Amputation .
| NCT ID | NCT07640516 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Kasr El Aini Hospital |
| Condition | Analgesia Assessment |
| Study Type | INTERVENTIONAL |
| Enrollment | 64 participants |
| Start Date | 2026-07-01 |
| Primary Completion | 2027-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 64 participants in total. It began in 2026-07-01 with a primary completion date of 2027-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to compare the analgesic efficacy and safety of dexmedetomidine versus fentanyl as adjuvants to bupivacaine in ultrasound-guided combined supra-inguinal fascia iliaca and proximal sciatic nerve blocks used as a solo anesthetic technique in high-risk patients undergoing unilateral above knee amputation.
Eligibility Criteria
Inclusion Criteria: * \- Age ≥18 years * Both sexes * ASA III-IV * Documented cardiac disease (e.g., EF \< 40%, NYHA II or higher) * Documented pulmonary disease (e.g., COPD with FEV1 \< 60%) * Scheduled for above-knee amputations Exclusion Criteria: * Neurological or intellectual disability * Drug abuse * Allergy to study drugs * Pregnancy * Contraindications to regional anesthesia (e.g., coagulopathy, local infection) * Significant renal or hepatic impairment( plts \<75000 or INR \>1.5) * Current anticoagulant therapy * severe haemodynamically unstability at the time of block performance, defined as map \> 65 mmhg but achieved by high-dose vasopressors (e.g., norepinephrine ≥ 0.1 mcg/kg/min) after fluid ressuscitation .
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07640516 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Analgesia Assessment. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07640516 currently recruiting?
Yes, NCT07640516 is actively recruiting participants. Contact the research team at paula.atef.gobran.1995@gmail.com for enrollment information.
Where is the NCT07640516 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT07640516 clinical trial?
NCT07640516 is sponsored by Kasr El Aini Hospital. The trial plans to enroll 64 participants.